Detail akcie TG Therap online

Business Summary: TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, TG Therapeutics Inc revenues increased 92% to $423.7M. Net income increased from $52K to $424.1M. Revenues reflect License, milestone and other revenue increase from $14.4M to $124.4M, Product increase of 45% to $299.4M. Net income benefited from Noncash compensation decrease of 24% to $36M (expense), Other income increase of 84% to $9.7M (income).